Dr. Reddy's Laboratories unveils Valsartan Tablets, USP in the US Market
9 December 2021 -

Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124)(NSE:DRREDDY)(NYSE:RDY) on Thursday reported the availability of Valsartan Tablets, USP in 40mg in bottle count size of 30; and 80mg, 160mg and 320mg tablets in bottle count sizes of 90 across the US.

The company added that the Valsartan Tablets, USP is the therapeutic equivalent generic version of Diovan (valsartan) Tablets approved by the U.S. Food and Drug Administration (USFDA).

According to IQVIA Health, the Diovan brand and generic market had US sales of approximately USD150m MAT for the most recent 12 months ending in October 2021.

Valsartan is a medicine used to treat high blood pressure and heart disease. Lowering blood pressure helps to prevent future heart attack and stroke. This medicine is also effective in preserving kidney function in patients with diabetes, concluded the company.



Related Headlines